{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-028531","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.773631+00:00","generated_at":"2026-05-24T04:00:22.101726+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bicycle Therapeutics appoints Alessandro Riva to board, names Felix Baker chairman, promotes Eric Westin to CMO","bullets":["Pierre Legault and Richard Kender to retire from board after AGM June 17, 2025; Felix Baker to become chairman.","Alessandro Riva joins board and scientific committee; receives annual cash $60k, option 25k shares, RSU 12.5k shares vesting over 3 years.","CDO Santiago Arroyo resigned March 24; separation includes pro-rated 2025 bonus, COBRA to May 2025; consulting fee $12k/yr, equity continues vesting.","Eric Westin promoted to CMO; Jim MacDonald-Clink promoted to SVP head of business development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-028531","json":"https://secwatch.observer/filing/0001104659-25-028531.json","markdown":"https://secwatch.observer/filing/0001104659-25-028531.md","text":"https://secwatch.observer/filing/0001104659-25-028531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/tm2510464d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:00:22.101726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"58e28d8166","claim":"Pierre Legault resigned as Director at BICYCLE THERAPEUTICS PLC.","evidence_excerpt":"On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}]},{"claim_id":"70ab0d3e91","claim":"Santiago Arroyo resigned as Chief Development Officer at BICYCLE THERAPEUTICS PLC.","evidence_excerpt":"Santiago Arroyo, M.D., Ph.D., notified the Board of his resignation as the Company's Chief Development Officer, effective March 24, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Development Officer"}]},{"claim_id":"dc021c9a03","claim":"Richard Kender resigned as Director at BICYCLE THERAPEUTICS PLC.","evidence_excerpt":"On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}]},{"claim_id":"f128d1aad2","claim":"Alessandro Riva was appointed as Director at BICYCLE THERAPEUTICS PLC.","evidence_excerpt":"appointed Alessandro Riva, M.D., to the Board and the Scientific Committee of the Board, effective as of the close of business on March 25, 2025, New York City time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}